Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Glucocorticoids, their uses, sexual dimorphisms, and diseases: new concepts, mechanisms, and discoveries
The normal stress response in humans is governed by the hypothalamic-pituitary-adrenal
(HPA) axis through heightened mechanisms during stress, raising blood levels of the …
(HPA) axis through heightened mechanisms during stress, raising blood levels of the …
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in
the liver in combination with metabolic dysfunction in the form of overweight or obesity and …
the liver in combination with metabolic dysfunction in the form of overweight or obesity and …
Hepatic insulin receptor: new views on the mechanisms of liver disease
Over 65% of people with obesity display the metabolic-associated fatty liver disease
(MAFLD), which can manifest as steatohepatitis, fibrosis, cirrhosis, or liver cancer. The …
(MAFLD), which can manifest as steatohepatitis, fibrosis, cirrhosis, or liver cancer. The …
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity
Tissue fibrosis is a key driver of end-stage organ failure and cancer, overall accounting for
up to 45% of deaths in developed countries. There is a large unmet medical need for …
up to 45% of deaths in developed countries. There is a large unmet medical need for …
Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome,
and is estimated to affect one billion individuals worldwide. An increased intake of a high-fat …
and is estimated to affect one billion individuals worldwide. An increased intake of a high-fat …
Loss of hepatic PPARα in mice causes hypertension and cardiovascular disease
The leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD) is
cardiovascular disease (CVD). However, the mechanisms are unknown. Mice deficient in …
cardiovascular disease (CVD). However, the mechanisms are unknown. Mice deficient in …
Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice
Hearing loss is a major health concern in our society, affecting more than 400 million people
worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss …
worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss …
Suppressing hepatic UGT1A1 increases plasma bilirubin, lowers plasma urobilin, reorganizes kinase signaling pathways and lipid species and improves fatty liver …
Several population studies have observed lower serum bilirubin levels in patients with non-
alcoholic fatty liver disease (NAFLD). Yet, treatments to target this metabolic phenotype have …
alcoholic fatty liver disease (NAFLD). Yet, treatments to target this metabolic phenotype have …
Bilirubin nanoparticle treatment in obese mice inhibits hepatic ceramide production and remodels liver fat content
Studies have indicated that increasing plasma bilirubin levels might be useful for preventing
and treating hepatic lipid accumulation that occurs with metabolic diseases such as obesity …
and treating hepatic lipid accumulation that occurs with metabolic diseases such as obesity …
[HTML][HTML] Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
The rising rates of obesity worldwide have increased the incidence of cardiovascular
disease (CVD), making it the number one cause of death. Higher plasma bilirubin levels …
disease (CVD), making it the number one cause of death. Higher plasma bilirubin levels …